Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 200 | $11.23 | 44,100 | |
| Apr 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 200 | $11.25 | 43,900 | |
| Apr 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $11.29 | 43,800 | |
| Apr 01, 2008 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 220 | $11.49 | 36,035 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 548 | $11.00 | 42,818 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 207 | $11.01 | 42,611 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $11.11 | 42,511 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $11.20 | 42,411 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 53 | $11.22 | 42,358 | |
| Apr 01, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $11.23 | 42,258 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.